Handelsbanken Fonder AB Has $102.60 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Handelsbanken Fonder AB boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 231.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,203,504 shares of the medical research company’s stock after acquiring an additional 840,513 shares during the quarter. Handelsbanken Fonder AB’s holdings in Edwards Lifesciences were worth $102,599,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in EW. Brighton Jones LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $266,000. NewEdge Advisors LLC grew its position in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after acquiring an additional 2,665 shares during the last quarter. Sei Investments Co. grew its position in Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares during the last quarter. Squarepoint Ops LLC grew its position in Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after acquiring an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its position in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after acquiring an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $82.39 on Tuesday. The stock’s 50 day moving average is $81.48 and its 200 day moving average is $82.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market cap of $47.44 billion, a P/E ratio of 43.82, a P/E/G ratio of 2.04 and a beta of 0.87. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the firm earned $0.64 earnings per share. The company’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares in the company, valued at $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 106,684 shares of company stock worth $8,811,739 over the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on EW shares. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Wells Fargo & Company lifted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Robert W. Baird lifted their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research report on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.